Melatonin stimulates the nonamyloidogenic processing of βaPP through the positive transcriptional regulation of ADAM10 and ADAM17

Journal of Pineal Research

Volumn 58, Issue 2, 2015, Pages 151-165

  Shukla, Mayuri ^a   Htoo, Htut Htut ^a   Wintachai, Phitchayapak ^a   Hernandez, Jean Francois ^b   Dubois, Claire ^c   Postina, Rolf ^d   Xu, Huaxi ^e,f   Checler, Frédéric ^g   Smith, Duncan R ^a   Govitrapong, Piyarat ^a,h   Vincent, Bruno ^a,i  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e XIAMEN UNIVERSITY   (China)

^f BURNHAM INSTITUTE   (United States)

^g INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^h Centre National de la Recherche Scientifique ^*  (Thailand)

ⁱ CNRS   (France)

Author keywords

Alzheimer; apoptosis; melatonin; metabolism; secretase; transcription

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; MELATONIN; MELATONIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAUROSPORINE; UNCLASSIFIED DRUG; ADAM10 PROTEIN, HUMAN; MEMBRANE PROTEIN; SECRETASE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; ENZYME PHOSPHORYLATION; FIBROBLAST; GENETIC REGULATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NERVE CELL; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSLATION INITIATION; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION;

ADAM PROTEINS; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; APOPTOSIS; BLOTTING, WESTERN; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MELATONIN; MEMBRANE PROTEINS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC;

EID: 84922771460     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12200     Document Type: Article

References (73)

1. Reiter RJ, Tan DX, Rosales-Corral SA, et al. The universal nature, unequal distribution and antioxidant function of melatonin and its derivatives. Mini-Rev Med Chem 2013; 13: 373-384.
2. Pandi-Perumal SR, Srinivasan V, Spence DW, et al. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs 2007; 21: 995-1018.
3. Tain YL, Leu S, Wu KLH, et al. Melatonin prevents maternal fructose intake-induced programmed hypertension in the offspring: roles of nitric oxide and arachidonic acid metabolites. J Pineal Res 2014; 57: 80-89.
4. Zhang HM, Zhang Y,. Melatonin, a well-documented antioxidant with conditional pro-oxidant activity. J Pineal Res 2014; 57: 131-146.
5. Waldhauser F, Steger H,. Changes in melatonin secretion with age and pubescence. J Neural Transm Suppl 1986; 21: 183-197.
6. Waldhauser F, Weiszenbacher G, Tatzer E, et al. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988; 66: 648-652.
7. Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990; 528: 170-174.
8. Ohashi Y, Okamoto N, Uchida K, et al. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999; 45: 1646-1652.
9. Liu RY, Zhou JN, van Heerikhuize J, et al. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-{epsilon}4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323-327.
10. Mishima K, Tozawa T, Satoh K, et al. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999; 45: 417-421.
11. Zhou JN, Liu RY, Kamphorst W, et al. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003; 35: 125-130.
12. Smith MA, Hirai K, Hsiao K, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212-2215.
13. Galano A, Tan DX, Reiter RJ,. Melatonin is a natural ally against oxidative stress: a physiochemical examination. J Pineal Res 2011; 51: 1-16.
14. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin and its metabolites. J Pineal Res 2013; 54: 245-257.
15. Rosales-Corral SA, Acuna-Castroviejo D, Cotomontes A, et al. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012; 52: 167-202.
16. Lin L, Huang QX, Yang SS, et al. Melatonin in Alzheimer's disease. Int J Mol Sci 2013; 14: 14575-14593.
17. Pappolla MA, Bozner P, Soto C, et al. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185-7188.
18. Pappolla MA, Sos M, Omar RA, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17: 1683-1690.
19. Feng Z, Chang Y, Cheng Y, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. J Pineal Res 2004; 37: 129-136.
20. Feng Z, Zhang JT,. Protective effect of melatonin on β-amyloid-induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Rad Biol Med 2004; 37: 1790-1801.
21. Jang MH, Jung SB, Lee MH, et al. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells. Neurosci Lett 2005; 380: 26-31.
22. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 1101-1108.
23. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009; 47: 82-96.
24. Quinn J, Kulhanek D, Nowlin J, et al. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implication for clinical trials. Brain Res 2005; 1037: 209-213.
25. Lahiri DK,. Melatonin affects the metabolism of the β-amyloid precursor protein in different cell types. J Pineal Res 1999; 26: 137-146.
26. Vincent B, Govitrapong P,. Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer's disease. J Alzheimers Dis 2011; 24: 75-94.
27. Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006; 49: 671-682.
28. Anton-Tay F, Ramirez G, Martinez I, et al. In vitro stimulation of protein kinase C by melatonin. Neurochem Res 1998; 23: 601-606.
29. Marambaud P, Chevallier N, Barelli H, et al. Proteasome contributes to the α-secretase pathway of amyloid precursor protein in human cells. J Neurochem 1997; 68: 698-703.
30. Vincent B, Paitel E, Frobert Y, et al. Phorbol ester-regulated cleavage of normal prion protein in HEK293 human cells and murine neurons. J Biol Chem 2000; 275: 35612-35616.
31. Nitsch RM, Slack BE, Wurtman RJ, et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-307.
32. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17: 1005-1013.
33. Hartmann D, de Strooper B, Serneels L, et al. The disintegrin/metalloprotease ADAM10 is essential for notch signaling but not for α-secretase activity in fibroblasts. Hum Mol Genet 2002; 11: 2615-2624.
34. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
35. Bradford MM,. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-259.
36. Alfa Cisse M, Gandreuil C, Hernandez JF, et al. Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of α-secretase. Biochem Biophys Res Commun 2006; 347: 254-260.
37. Prinzen C, Muller U, Endres K, et al. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 2005; 19: 1522-1524.
38. Charbonneau M, Harper K, Grondin F, et al. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor α-induced increases in tumor necrosis factor-α converting enzyme/ADAM17 expression by synovial cells. J Biol Chem 2007; 282: 33714-33724.
39. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999; 96: 3922-3927.
40. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998; 273: 27765-27767.
41. Tosini G, Owino S, Guillaume JL, et al. Understanding melatonin receptor pharmacology: latest insights from mouse model, and their relevance to human disease. BioEssays 2014; 36: 778-787.
42. Zhang YC, Wang ZF, Wang Q, et al. Melatonin attenuates β-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin 2004; 25: 447-451.
43. Wang XC, Zhang YC, Chatterjie N, et al. Effect of melatonin and melatonylvalpromide on β-amyloid and neurofilaments in N2a cells. Neurochem Res 2008; 33: 1138-1144.
44. Olivieri G, Hess C, Savaskan E, et al. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased β-amyloid secretion. J Pineal Res 2001; 31: 320-325.
45. Bender Hoppe J, Frozza RL, Horn AP, et al. Amyloid-β neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK3β, tau and neuroinflammation. J Pineal Res 2010; 48: 230-238.
46. Ionov M, Burchell V, Klajnert B, et al. Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience 2011; 180: 229-237.
47. Clapp-Lilly KL, Smith MA, Perry G, et al. Melatonin reduces interleukin secretion in amyloid-β stressed mouse brain slices. Chem Biol Interact 2001; 134: 101-107.
48. Lahiri DK, Chen D, Ge YW, et al. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. J Pineal Res 2004; 36: 224-231.
49. Song W, Lahiri DK,. Melatonin alters the metabolism of the β-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 1997; 9: 75-92.
50. Acuna-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014; 71: 2997-3025.
51. Guardiola-Lemaitre B,. Toxicology of melatonin. J Biol Rhythms 1997; 12: 697-706.
52. Conway S, Drew JE, Canning SJ, et al. Identification of Mel1a melatonin receptors in the human embryonic kidney cell line HEK293: evidence of G-protein-coupled melatonin receptors which do not mediate the inhibition of stimulated cyclic AMP levels. FEBS Lett 1997; 407: 121-126.
53. Naji L, Carillo-Vico A, Guerrero JM, et al. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74: 2227-2236.
54. Chen L, He X, Zhang Y, et al. Melatonin receptor type 1 signals to extracellular signal-regulated kinase 1 and 2 via Gi and Gs dually coupled pathways in HEK-293 cells. Biochemistry 2014; 53: 2827-2839.
55. Barsoum IB, Hamilton TK, Li X, et al. Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 2011; 71: 7433-7441.
56. Dai M, Cui P, Yu M, et al. Melatonin modulates the expression of VEGF and HIF-1α induced by CoCl2 in cultured cancer cells. J Pineal Res 2008; 44: 121-126.
57. Park JW, Hwang MS, Suh SI, et al. Melatonin down-regulates HIF-1α expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 2009; 46: 415-421.
58. Park SY, Jang WJ, Yi EY, et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J Pineal Res 2010; 48: 178-184.
59. Xing J, Ginty DD, Greenberg ME,. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996; 273: 959-963.
60. Tong T, Fan W, Zhao H, et al. Involvement of the MAP kinase pathways in induction of GADD45 following UV radiation. Exp Cell Res 2001; 269: 64-72.
61. Richard DE, Berra E, Gothie E, et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 174: 32631-32637.
62. Skovronski DM, Fath S, Lee VMY, et al. Neuronal localization of the TNFα converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. J Neurobiol 2001; 49: 40-46.
63. Colciaghi F, Borroni B, Pastorino L, et al. α-secretase ADAM10 as well as αAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 2002; 8: 67-74.
64. Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM10 and BACE alterations in the early stages of Alzheimer disease. Neurology 2004; 62: 498-501.
65. Savaskan E, Olivieri G, Meier F, et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. J Pineal Res 2002; 32: 59-62.
66. Savaskan E, Ayoub MA, Ravid R, et al. Reduced hippocampal MT2 melatonin receptor expression in Alzheimer's disease. J Pineal Res 2005; 38: 10-16.
67. Singh M, Jadhav HR,. Melatonin: functions and ligands. Drug Discov Today 2014; 19: 1410-1418.
68. Goodger ZV, Rajendran L, Trutzel A, et al. Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci 2009; 122: 3703-3714.
69. Belyaev ND, Kellett KA, Beckett C, et al. The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a beta-secretase-dependent pathway. J Biol Chem 2010; 285: 41443-41454.
70. Flammang B, Pardossi-Piquard R, Sevalle J, et al. Evidence that the amyloid-β protein precursor intracellular domain, AICD, derives from β-secretase-generated C-terminal fragment. J Alzheimers Dis 2012; 30: 145-153.
71. Kim HS, Kim EM, Lee JP, et al. C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3β expression. FASEB J 2003; 17: 1951-1953.
72. Peng CX, Hu J, Liu D, et al. Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. Neurobiol Aging 2013; 34: 1555-1563.
73. Hardeland R,. Melatonin and the theories of aging is a critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res 2013; 55: 325-356.